After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Oct 19 (Reuters) - GoodRx (GDRX.O), opens new tab said on Thursday it has collaborated with Sanofi (SASY.PA), opens new tab to offer the drugmaker's most-prescribed insulin injection Lantus for only ...

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing both. Novo Nordisk is ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...